J&J Unit Fights Use Of New Topamax Label In Defect Suits

Law360, Philadelphia (March 5, 2014, 2:05 PM EST) -- A Johnson & Johnson unit said Tuesday that plaintiffs in a cluster of suits alleging that the anti-epilepsy drug Topamax caused birth defects had improperly asked a Pennsylvania judge to reconsider a decision over the admissibility of a 2011 label change strengthening warnings about risks to pregnant women.

Janssen Pharmaceuticals Inc. said that the Pennsylvania Supreme Court’s order in December nixing an appeal in Daniel v. Wyeth Pharmaceuticals — which dealt with the admissibility of labels that post-date a plaintiff’s use of a medication — did...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.